Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive brain circuits and the spread of tau in vivo in humans
2024-511613-38-01Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Aug 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of florquinitau in Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) (4 arms), sponsored by UZ Leuven. Planned start Aug 2024; status: authorised.
02
Drugs
florquinitau
03
Conditions
Alzheimer's disease (AD)amnestic mild cognitive impairment (MCI)
Beyond the preview
Go deeper on 2024-511613-38-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511613-38-01.